Takeda Pharmaceutical Co., Ltd.
0
0
0%

Financials

Income statement

Fiscal date Sep 2025 Jun 2025 Mar 2025 Dec 2024
Total reported revenue 1.1T 1.1T 1.1T 1.1T
Cost of revenue 380.1B 384.7B 382.1B 416.9B
Gross profit 732.7B 722.0B 671.3B 727.3B
Operating expense
Research & development 161.5B 143.9B 216.0B 170.2B
Selling general and admin 253.6B 255.9B 295.9B 270.6B
Other operating expenses 43.6B 6.0B -112.2B 146.2B
Operating income 69.0B 184.6B 68.5B -22.4B
Non operating interest income
Income 44.4B 73.8B -8.2B -7.0B
Expense 83.1B 107.2B -22.4B 31.6B
Other income expense -2.1B -536M -166.1B 87.4B
Pretax income 28.2B 150.6B -107.3B 26.4B
Tax provision 39.9B 26.4B -4.2B 2.6B
Net income -11.7B 124.3B -103.1B 23.8B
Basic EPS 79.4
Diluted EPS 78.2
Basic average shares 1.6B
Diluted average shares 1.6B
EBITDA 316.5B 439.4B 73.3B 245.0B
Net income from continuing op. -11.7B 124.3B -103.1B 23.8B
Minority interests -72M -36M -57M -46M
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Main market

Exchange is currently active.
Closing in 6 hours 11 minutes

09:18
00:00
09:00
15:30
23:59

Trading Hours (Monday - Friday):

Main market
09:00 - 15:30
All times are displayed in the Asia/Tokyo timezone (JST, UTC+09:00).